ecrin-mdr-crcClinical2013Colorectal NeoplasmsColorectal Cancer MetastaticIPD Sharing (as of January 2023): NoColorectal NeoplasmsColorectal Cancer MetastaticObservationalhttps://newmdr.ecrin.org/Study/912271ECRIN MDRCompletedfalseChemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver MetastasesChemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients. Those with KRAS/NRAS/BRAF mutated tumors or cycle of conversion therapy ≤ 4 can benefit more from chemotharapy plus targeted therapyrather than from chemotharapy alone, with a tolerable toxicity profile.2013-01-1591227NCT06027775